Authors: Anita Jacob, Anushree Patel, Hannah Joseph, KB Sneed, Yashwant Pathak.
Respiratory Syncytial Virus (RSV), a respiratory tract infection-causing virus with a global distribution and seasonal occurrence, is the second leading cause of death in children under one year old, after malaria. The Respiratory Syncytial virus is an enveloped negative-strand RNA virus from the Paramyxoviridae family primarily transmitted by droplets of a cough or sneeze. However, kisses between infected and healthy individuals can also rapidly spread the virus, especially among children. Typically, the virus causes symptoms such as coughing, sneezing, or a fever making it visibly like other infections or conditions. Young children may have apnea and overall be irritable. Confirmation of RSV diagnosis can be done through available RSV-card tests or through RT-PCR tests. Though there is no standard treatment for RSV infection, drugs such as Ribavirin and Synagis® (Palivizumab) are currently used for managing symptoms of RSV infection in areas that have access to such medications. Palivizumab is used to treat prophylaxis, the prevention of serious lower respiratory tract disease brought on by RSV in children at high risk of RSV disease, is the greatest preventative approach. Numerous clinical studies are being conducted right now to treat and prevent RSV infection. Most of the study focuses on children below the age of 5 years because they are the most vulnerable, but there is also research on the prevalence of RSV in older adults and the effects of maternal vaccination on infants through the antibodies made to fight against RSV infection. G protein, F protein, and SH protein are three crucial membrane proteins that make up the RSV structure. A vaccine containing both the F and G RSV proteins would offer more protection against RSV. The F and G protein stimulates antibody formation, which neutralizes the virus. The RSV treatment plans and vaccine trials within India, South Africa, the United States of America, and the United Kingdom show similarities and differences that could be utilized to develop a treatment plan for RSV. In the upcoming years, further research is required to produce a cheaper alternative that is accessible to all countries. This will help to establish a set, effective protocol for RSV to be used worldwide.
View/Download pdf